 | • レポートコード：MRC23Q36125 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の自己免疫疾患におけるキナーゼ阻害剤市場について調査・分析し、世界の自己免疫疾患におけるキナーゼ阻害剤市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（理学療法、外科、その他）、用途別セグメント分析（抗炎症薬、コルチコステロイド、鎮痛薬、免疫抑制薬）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer、Reistone Biopharma、Eli Lily and Company、AbbVie、Gilead Sciences、Astellas Pharma、Japan Tobacco and Torii Pharmaceutical、Incyte Corporation、Bristol Myers Squibb、Galapagos NVなどが含まれています。 世界の自己免疫疾患におけるキナーゼ阻害剤市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、自己免疫疾患におけるキナーゼ阻害剤市場規模を推定する際に考慮しました。本レポートは、自己免疫疾患におけるキナーゼ阻害剤の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、自己免疫疾患におけるキナーゼ阻害剤に関するビジネス上の意思決定に役立てることを目的としています。 ・自己免疫疾患におけるキナーゼ阻害剤市場の概要 - 自己免疫疾患におけるキナーゼ阻害剤のタイプ別セグメント - 世界の自己免疫疾患におけるキナーゼ阻害剤市場規模：タイプ別分析（理学療法、外科、その他） - 自己免疫疾患におけるキナーゼ阻害剤の用途別セグメント - 世界の自己免疫疾患におけるキナーゼ阻害剤市場規模：用途別分析（抗炎症薬、コルチコステロイド、鎮痛薬、免疫抑制薬） - 世界の自己免疫疾患におけるキナーゼ阻害剤市場規模予測（2018年-2029年） ・自己免疫疾患におけるキナーゼ阻害剤市場の成長トレンド - 自己免疫疾患におけるキナーゼ阻害剤の地域別市場規模（2018年-2029年） - 自己免疫疾患におけるキナーゼ阻害剤市場ダイナミクス - 自己免疫疾患におけるキナーゼ阻害剤の業界動向 - 自己免疫疾患におけるキナーゼ阻害剤市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：理学療法、外科、その他 - 世界の自己免疫疾患におけるキナーゼ阻害剤のタイプ別市場規模（2018年-2023年） - 世界の自己免疫疾患におけるキナーゼ阻害剤のタイプ別市場規模（2024年-2029年） ・用途別セグメント：抗炎症薬、コルチコステロイド、鎮痛薬、免疫抑制薬 - 世界の自己免疫疾患におけるキナーゼ阻害剤の用途別市場規模（2018年-2023年） - 世界の自己免疫疾患におけるキナーゼ阻害剤の用途別市場規模（2024年-2029年） ・自己免疫疾患におけるキナーゼ阻害剤の地域別市場規模 - 北米の自己免疫疾患におけるキナーゼ阻害剤市場規模（2018年-2029年） - アメリカの自己免疫疾患におけるキナーゼ阻害剤市場規模（2018年-2029年） - ヨーロッパの自己免疫疾患におけるキナーゼ阻害剤市場規模（2018年-2029年） - アジア太平洋の自己免疫疾患におけるキナーゼ阻害剤市場規模（2018年-2029年） - 中国の自己免疫疾患におけるキナーゼ阻害剤市場規模（2018年-2029年） - 日本の自己免疫疾患におけるキナーゼ阻害剤市場規模（2018年-2029年） - 韓国の自己免疫疾患におけるキナーゼ阻害剤市場規模（2018年-2029年） - インドの自己免疫疾患におけるキナーゼ阻害剤市場規模（2018年-2029年） - オーストラリアの自己免疫疾患におけるキナーゼ阻害剤市場規模（2018年-2029年） - 中南米の自己免疫疾患におけるキナーゼ阻害剤市場規模（2018年-2029年） - 中東・アフリカの自己免疫疾患におけるキナーゼ阻害剤市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Pfizer、Reistone Biopharma、Eli Lily and Company、AbbVie、Gilead Sciences、Astellas Pharma、Japan Tobacco and Torii Pharmaceutical、Incyte Corporation、Bristol Myers Squibb、Galapagos NV ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Kinase Inhibitor in Autoimmune Diseases market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Kinase Inhibitor in Autoimmune Diseases is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Kinase Inhibitor in Autoimmune Diseases is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Kinase Inhibitor in Autoimmune Diseases in Anti-inflammatory Drugs is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Kinase Inhibitor in Autoimmune Diseases include Pfizer, Reistone Biopharma, Eli Lily and Company, AbbVie, Gilead Sciences, Astellas Pharma, Japan Tobacco and Torii Pharmaceutical, Incyte Corporation and Bristol Myers Squibb, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Kinase Inhibitor in Autoimmune Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kinase Inhibitor in Autoimmune Diseases.
The Kinase Inhibitor in Autoimmune Diseases market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Kinase Inhibitor in Autoimmune Diseases market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kinase Inhibitor in Autoimmune Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Reistone Biopharma
Eli Lily and Company
AbbVie
Gilead Sciences
Astellas Pharma
Japan Tobacco and Torii Pharmaceutical
Incyte Corporation
Bristol Myers Squibb
Galapagos NV
Segment by Type
Physical Therapy
Surgery
Others
Segment by Application
Anti-inflammatory Drugs
Corticosteroids
Pain-killing Medications
Immunosuppressants
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kinase Inhibitor in Autoimmune Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kinase Inhibitor in Autoimmune Diseases Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Physical Therapy
1.2.3 Surgery
1.2.4 Others
1.3 Market by Application
1.3.1 Global Kinase Inhibitor in Autoimmune Diseases Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Anti-inflammatory Drugs
1.3.3 Corticosteroids
1.3.4 Pain-killing Medications
1.3.5 Immunosuppressants
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kinase Inhibitor in Autoimmune Diseases Market Perspective (2018-2029)
2.2 Kinase Inhibitor in Autoimmune Diseases Growth Trends by Region
2.2.1 Global Kinase Inhibitor in Autoimmune Diseases Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Kinase Inhibitor in Autoimmune Diseases Historic Market Size by Region (2018-2023)
2.2.3 Kinase Inhibitor in Autoimmune Diseases Forecasted Market Size by Region (2024-2029)
2.3 Kinase Inhibitor in Autoimmune Diseases Market Dynamics
2.3.1 Kinase Inhibitor in Autoimmune Diseases Industry Trends
2.3.2 Kinase Inhibitor in Autoimmune Diseases Market Drivers
2.3.3 Kinase Inhibitor in Autoimmune Diseases Market Challenges
2.3.4 Kinase Inhibitor in Autoimmune Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kinase Inhibitor in Autoimmune Diseases Players by Revenue
3.1.1 Global Top Kinase Inhibitor in Autoimmune Diseases Players by Revenue (2018-2023)
3.1.2 Global Kinase Inhibitor in Autoimmune Diseases Revenue Market Share by Players (2018-2023)
3.2 Global Kinase Inhibitor in Autoimmune Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Kinase Inhibitor in Autoimmune Diseases Revenue
3.4 Global Kinase Inhibitor in Autoimmune Diseases Market Concentration Ratio
3.4.1 Global Kinase Inhibitor in Autoimmune Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kinase Inhibitor in Autoimmune Diseases Revenue in 2022
3.5 Kinase Inhibitor in Autoimmune Diseases Key Players Head office and Area Served
3.6 Key Players Kinase Inhibitor in Autoimmune Diseases Product Solution and Service
3.7 Date of Enter into Kinase Inhibitor in Autoimmune Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Kinase Inhibitor in Autoimmune Diseases Breakdown Data by Type
4.1 Global Kinase Inhibitor in Autoimmune Diseases Historic Market Size by Type (2018-2023)
4.2 Global Kinase Inhibitor in Autoimmune Diseases Forecasted Market Size by Type (2024-2029)
5 Kinase Inhibitor in Autoimmune Diseases Breakdown Data by Application
5.1 Global Kinase Inhibitor in Autoimmune Diseases Historic Market Size by Application (2018-2023)
5.2 Global Kinase Inhibitor in Autoimmune Diseases Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Kinase Inhibitor in Autoimmune Diseases Market Size (2018-2029)
6.2 North America Kinase Inhibitor in Autoimmune Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Kinase Inhibitor in Autoimmune Diseases Market Size by Country (2018-2023)
6.4 North America Kinase Inhibitor in Autoimmune Diseases Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kinase Inhibitor in Autoimmune Diseases Market Size (2018-2029)
7.2 Europe Kinase Inhibitor in Autoimmune Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Kinase Inhibitor in Autoimmune Diseases Market Size by Country (2018-2023)
7.4 Europe Kinase Inhibitor in Autoimmune Diseases Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kinase Inhibitor in Autoimmune Diseases Market Size (2018-2029)
8.2 Asia-Pacific Kinase Inhibitor in Autoimmune Diseases Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Kinase Inhibitor in Autoimmune Diseases Market Size by Region (2018-2023)
8.4 Asia-Pacific Kinase Inhibitor in Autoimmune Diseases Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kinase Inhibitor in Autoimmune Diseases Market Size (2018-2029)
9.2 Latin America Kinase Inhibitor in Autoimmune Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Kinase Inhibitor in Autoimmune Diseases Market Size by Country (2018-2023)
9.4 Latin America Kinase Inhibitor in Autoimmune Diseases Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kinase Inhibitor in Autoimmune Diseases Market Size (2018-2029)
10.2 Middle East & Africa Kinase Inhibitor in Autoimmune Diseases Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Kinase Inhibitor in Autoimmune Diseases Market Size by Country (2018-2023)
10.4 Middle East & Africa Kinase Inhibitor in Autoimmune Diseases Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Kinase Inhibitor in Autoimmune Diseases Introduction
11.1.4 Pfizer Revenue in Kinase Inhibitor in Autoimmune Diseases Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Reistone Biopharma
11.2.1 Reistone Biopharma Company Detail
11.2.2 Reistone Biopharma Business Overview
11.2.3 Reistone Biopharma Kinase Inhibitor in Autoimmune Diseases Introduction
11.2.4 Reistone Biopharma Revenue in Kinase Inhibitor in Autoimmune Diseases Business (2018-2023)
11.2.5 Reistone Biopharma Recent Development
11.3 Eli Lily and Company
11.3.1 Eli Lily and Company Company Detail
11.3.2 Eli Lily and Company Business Overview
11.3.3 Eli Lily and Company Kinase Inhibitor in Autoimmune Diseases Introduction
11.3.4 Eli Lily and Company Revenue in Kinase Inhibitor in Autoimmune Diseases Business (2018-2023)
11.3.5 Eli Lily and Company Recent Development
11.4 AbbVie
11.4.1 AbbVie Company Detail
11.4.2 AbbVie Business Overview
11.4.3 AbbVie Kinase Inhibitor in Autoimmune Diseases Introduction
11.4.4 AbbVie Revenue in Kinase Inhibitor in Autoimmune Diseases Business (2018-2023)
11.4.5 AbbVie Recent Development
11.5 Gilead Sciences
11.5.1 Gilead Sciences Company Detail
11.5.2 Gilead Sciences Business Overview
11.5.3 Gilead Sciences Kinase Inhibitor in Autoimmune Diseases Introduction
11.5.4 Gilead Sciences Revenue in Kinase Inhibitor in Autoimmune Diseases Business (2018-2023)
11.5.5 Gilead Sciences Recent Development
11.6 Astellas Pharma
11.6.1 Astellas Pharma Company Detail
11.6.2 Astellas Pharma Business Overview
11.6.3 Astellas Pharma Kinase Inhibitor in Autoimmune Diseases Introduction
11.6.4 Astellas Pharma Revenue in Kinase Inhibitor in Autoimmune Diseases Business (2018-2023)
11.6.5 Astellas Pharma Recent Development
11.7 Japan Tobacco and Torii Pharmaceutical
11.7.1 Japan Tobacco and Torii Pharmaceutical Company Detail
11.7.2 Japan Tobacco and Torii Pharmaceutical Business Overview
11.7.3 Japan Tobacco and Torii Pharmaceutical Kinase Inhibitor in Autoimmune Diseases Introduction
11.7.4 Japan Tobacco and Torii Pharmaceutical Revenue in Kinase Inhibitor in Autoimmune Diseases Business (2018-2023)
11.7.5 Japan Tobacco and Torii Pharmaceutical Recent Development
11.8 Incyte Corporation
11.8.1 Incyte Corporation Company Detail
11.8.2 Incyte Corporation Business Overview
11.8.3 Incyte Corporation Kinase Inhibitor in Autoimmune Diseases Introduction
11.8.4 Incyte Corporation Revenue in Kinase Inhibitor in Autoimmune Diseases Business (2018-2023)
11.8.5 Incyte Corporation Recent Development
11.9 Bristol Myers Squibb
11.9.1 Bristol Myers Squibb Company Detail
11.9.2 Bristol Myers Squibb Business Overview
11.9.3 Bristol Myers Squibb Kinase Inhibitor in Autoimmune Diseases Introduction
11.9.4 Bristol Myers Squibb Revenue in Kinase Inhibitor in Autoimmune Diseases Business (2018-2023)
11.9.5 Bristol Myers Squibb Recent Development
11.10 Galapagos NV
11.10.1 Galapagos NV Company Detail
11.10.2 Galapagos NV Business Overview
11.10.3 Galapagos NV Kinase Inhibitor in Autoimmune Diseases Introduction
11.10.4 Galapagos NV Revenue in Kinase Inhibitor in Autoimmune Diseases Business (2018-2023)
11.10.5 Galapagos NV Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details